Brokerages Set Elanco Animal Health Incorporated (NYSE:ELAN) Target Price at $29.09

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have earned an average recommendation of “Moderate Buy” from the thirteen analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, nine have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $29.0909.

Several equities analysts recently issued reports on the stock. Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. Morgan Stanley boosted their price target on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Wednesday, July 22nd. UBS Group increased their price target on Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, KeyCorp raised their price objective on Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th.

Elanco Animal Health Stock Up 0.2%

Shares of NYSE:ELAN opened at $24.48 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $12.23 billion, a P/E ratio of -59.71, a P/E/G ratio of 1.82 and a beta of 1.68. Elanco Animal Health has a 52-week low of $17.51 and a 52-week high of $27.98. The stock’s fifty day simple moving average is $24.64 and its 200-day simple moving average is $23.97.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. The firm had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, equities research analysts forecast that Elanco Animal Health will post 1.12 earnings per share for the current fiscal year.

Insider Activity

In other Elanco Animal Health news, Director Lawrence Kurzius purchased 40,000 shares of the stock in a transaction on Thursday, August 20th. The stock was bought at an average price of $23.40 per share, for a total transaction of $936,000.00. Following the acquisition, the director directly owned 188,647 shares of the company’s stock, valued at $4,414,339.80. This represents a 26.91% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, Director Michael J. Harrington acquired 5,000 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were bought at an average cost of $21.82 per share, with a total value of $109,100.00. Following the purchase, the director owned 131,451 shares in the company, valued at approximately $2,868,260.82. The trade was a 3.95% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 63,198 shares of company stock valued at $1,473,109 in the last three months. Company insiders own 1.14% of the company’s stock.

Institutional Investors Weigh In On Elanco Animal Health

A number of institutional investors have recently bought and sold shares of ELAN. NewEdge Advisors LLC raised its stake in Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after purchasing an additional 627 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Elanco Animal Health during the 2nd quarter valued at $38,000. Root Financial Partners LLC grew its stake in shares of Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after buying an additional 592 shares during the period. Uniplan Investment Counsel Inc. acquired a new stake in shares of Elanco Animal Health during the 4th quarter worth $41,000. Finally, Bessemer Group Inc. increased its holdings in shares of Elanco Animal Health by 33.2% during the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after buying an additional 525 shares during the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.